Haemonetics Corporation (NYSE:HAE) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Moderate Buy consensus from 11 analysts (4 holds, 6 buys, 1 strong buy) with an average 12‑month target of $83.89.
• Earnings beat: Haemonetics reported $1.31 EPS vs $1.27 expected and $338.97M revenue vs $331.90M, and set FY2026 guidance of 4.900–5.000 EPS versus analysts' ~4.55 estimate.
• Shares opened at $58.53 (down 1.7%), market cap ~$2.72B, P/E 16.12, trading well below its 52‑week high of $87.32 and with ~99.7% institutional ownership.

Haemonetics Corporation (NYSE:HAE - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven research firms that are currently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $83.8889.

A number of brokerages recently issued reports on HAE. JPMorgan Chase & Co. lifted their price target on shares of Haemonetics from $62.00 to $74.00 and gave the stock a "neutral" rating in a research note on Friday, December 12th. Mizuho decreased their price target on shares of Haemonetics from $90.00 to $80.00 and set an "outperform" rating for the company in a research note on Friday, February 6th. Robert W. Baird set a $81.00 price target on shares of Haemonetics in a research note on Friday, February 6th. Barrington Research set a $94.00 price target on shares of Haemonetics in a research note on Friday, February 6th. Finally, Needham & Company LLC downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Monday, December 15th.

Haemonetics Trading Down 1.7%

Shares of HAE stock opened at $58.53 on Friday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.15 and a current ratio of 1.75. The stock has a market capitalization of $2.72 billion, a P/E ratio of 16.12, a price-to-earnings-growth ratio of 1.17 and a beta of 0.36. The company has a 50 day moving average price of $60.22 and a 200 day moving average price of $65.24. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $87.32.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.27 by $0.04. The firm had revenue of $338.97 million during the quarter, compared to analysts' expectations of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The business's quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Equities research analysts predict that Haemonetics will post 4.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in HAE. Kemnay Advisory Services Inc. purchased a new position in Haemonetics in the fourth quarter worth approximately $26,000. True Wealth Design LLC lifted its stake in Haemonetics by 6,700.0% in the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier's stock worth $27,000 after acquiring an additional 335 shares during the last quarter. Leonteq Securities AG purchased a new position in Haemonetics in the fourth quarter worth approximately $30,000. EverSource Wealth Advisors LLC lifted its stake in Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock worth $31,000 after acquiring an additional 396 shares during the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in Haemonetics in the fourth quarter worth approximately $34,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.